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Abstract
Diabetes mellitus is rapidly becoming one of the major diseases affecting people’s 
health globally. Over half of 100 million diabetes patients who need insulin to sur-
vive, especially in low- and middle-income countries (LMIC), are not able to get 
this medicine and die prematurely. Since 2000, insulin-producing companies have 
started support programmes with a component of insulin donations to children and 
youth with type 1 diabetes in 43 LMIC. Based on their experiences we conclude, 
contrary to common belief, that the diagnosis, treatment, and prevention of fatal 
complications in children with type 1 diabetes in LMIC are very possible in prac-
tice, with large improvements in survival, mean body weight, mean glucose levels, 
and frequency of complications. Medicine donations can never offer a sustainable 
solution and we now propose a ten-step transition process towards a fully sustain-
able national diabetes care and prevention programme for children and youth with 
diabetes type 1.
Keywords Diabetes type 1 · Children · Insulin · Medicine donations · Low- and 
middle-income countries · Essential medicines · Pharmaceutical companies
Introduction
Diabetes mellitus is rapidly becoming one of the major diseases affecting peo-
ple’s health globally. The World Health Organization (WHO) estimates that the 
prevalence among adults above 18 years of age has risen from 4.7% in 1980 to 
8.5% in 2014; this rise has been even more rapidly in low- and middle-income 
countries (LMIC). Diabetes is currently the seventh leading cause of death, with 
almost all deaths occurring before the age of 70 [1]. For about 100 million people 
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living with diabetes worldwide, daily injections with insulin are essential to pre-
vent premature death and a host of debilitating and potentially fatal complica-
tions, such as hypo- and hyperglycaemia, diabetic coma, cardiovascular disease, 
renal failure, gangrene of extremities, and blindness. However, more than half of 
them cannot obtain or afford this life-saving medicine, especially in LMIC [2]. 
Three-quarters of people living with diabetes are of working age, and the regular 
supply of insulin therefore offers an important opportunity to improve health at 
the population level.
The situation is especially dramatic in the case of insulin-dependent diabetes 
(‘diabetes type 1’), which usually manifests itself in teenaged children. In view 
of the organizational and financial complexities of recognizing the disease, teach-
ing and supporting the patients and their parents, and fulfilling the daily need 
of injectable insulin and some basic diagnostics to measure blood glucose lev-
els, in many LMIC the diagnosis and treatment of diabetes type 1 is not seen 
as a priority for health systems that are already overburdened; most patients and 
parents are simply left on their own. Although exact figures are lacking, a study 
published in 2016 estimated that, in the absence of daily insulin treatment, the 
average survival of children and youth with type 1 diabetes is less than 1  year 
[3]; most untreated patients succumb to the fatal complications of the disease and 
very few of them reach adulthood.
Three pharmaceutical companies, Novo Nordisk, Eli Lilly and Company, and 
Sanofi, produce 92–93% of all insulin consumed in the world [3]. While these 
companies maintain high prices in industrialized countries such as the United 
States (US), and in most LMIC, in the last two decades they have also established 
support programmes to promote access to insulin for poor and disadvantaged 
patients in LMIC. To do so they often work through separate foundations such as 
the International Diabetes Federation (IDF) and the World Diabetes Foundation 
(WDF). The impact of these donations has never been systematically assessed 
and published in the peer-reviewed literature.
In this Viewpoint, we argue that these insulin donations have now delivered the 
proof of concept that, contrary to common belief, diagnosis and treatment of type 
1 diabetes and the prevention of complications are very possible in LMIC. We 
also argue that these programmes can play a ‘pathfinder’ role in countries where 
the public sector is currently unable to provide insulin and where high prices in 
the private sector make insulin unaffordable. Finally, we present a ten-step pro-
cess to transfer the responsibility for diabetes prevention, care and treatment for 
children and youth from a donor-supported programme towards a national system 
of social security or health insurance.
From looking at the little publicly available information from relevant web-
sites, annual reports and press releases, conference presentations, the published 
and grey literature, and discussions with experts from international NGOs (WDF, 
IDF, Life For A Child (LFAC)] and national programmes (e.g. Cameroun, 
Guinea, Mali, Nigeria, Senegal, Tanzania), we make the following observations:
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Few company‑supported programmes include a component 
of donated insulin
We identified more than 40 different company-supported programmes for type 1 and 
2 diabetes education, prevention, diagnosis, treatment, and care in over 70 LMICs 
[4–13]. The IDF collaborates with 230 national diabetes organizations in 170 coun-
tries, and the WDF website lists nearly 400 separate partnerships in 117 countries 
[13]. Most of these projects focus on advocacy, prevention, screening, training of 
patients and health workers, establishment of treatment centres, supply of equip-
ment, and mobile clinics [14]. Few programmes include a component of donated 
insulin.
In 2001, the IDF launched the Life For A Child (LFAC) programme [15] to sup-
port children and youth with diabetes in the developing world with human insulin, 
syringes, blood glucose monitoring equipment, education materials, health worker 
training, treatment guidelines, research, infrastructure, capacity building, and voca-
tional training. Eli Lilly is the main supplier of free insulin and their largest dona-
tion is for this programme [16, 17]. In 2009, Novo Nordisk launched the Changing 
 Diabetes® in Children (CDiC) programme to improve delivery of care to children 
and youth with type 1 diabetes in resource-poor settings, supplying donated insu-
lin [18, 19]. In 2010, Novo Nordisk also started the Base of the Pyramid project, 
targeting the working poor in four LMIC by developing scalable, sustainable, and 
profitable solutions to increase diabetes care [20]. The WDF has facilitated some 
time-limited donation programmes in a few additional countries.
The number of children and young adults receiving donated insulin 
is increasing
From 2009 to 2015, the programmes with a component of free insulin covered 
43 LMICs [14], and focused on children and young adults with type 1 diabetes 
(Table 1). The estimated number of children and young adults benefitting from insu-
lin donations rose from 8193 in 2009 to 35,382 in 2015 (Fig. 1). Several countries 
Table 1  Country programmes with a component of donated insulin for patients with type 1 diabetes 
(2009–2015)
a Life For A Child
b World diabetes foundation
c Changing Diabetes in Children
Africa Burkina  Fasoa,  Burundia,  Cameroonb,c,  Congoa, Congo  DRa,b,c,  Eritreaa,  Ethiopiaa,b,c,  Ghanaa, 
 Guineac,  Kenyaa,b,c,  Malia,  Mauritaniaa,  Nigeriaa,b,  Rwandaa,  Sudana,b,  Tanzaniaa,b,c,  Togoa,  Ugandab,c, 
 Zimbabwea
Americas  Boliviaa, Cayman  Islandsa, Dominican  Republica,  Ecuadora,  Guatemalaa,  Guyanaa,  Haitia, 
 Jamaicaa,  Mexicoa
Asia/Oceania  Azerbadjiana,  Bangladesha,c,  Cambodiaa,  Chinab,  Fijia,  Indiac,  Maldivesa,  Nepala, 
 Pakistana,b, Papua New  Guineaa,  Philippinesa, Solomon  Islandsa,  Tajikistana,  Uzbekistana,  Vietnama
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showed dramatic increases in the number of patients covered. In Rwanda, the pro-
gramme started with 25 patients in 2004 and included 699 patients in 2014 [21]. 
Tanzania [22, 23] started with 50 registered patients and participation rose to 2116 
in 13 years; Mali [24] from 7 to 53 patients in 9 years, and Guinea [25] from 44 to 
448 patients in 4 years.
Most programmes also report large increases in the number of diabetes treatment 
centres. Rwanda increased facilities with such programmes from 10 in 2009 to 40 
hospitals in 2014 [21]. The programme in Tanzania started with one diabetes clinic 
in 2003 and has recently extended to 187 district hospitals [22]. In Guinea, the pro-
gramme grew from nine hospitals in 2009 to 64 hospitals in 2013 [25], and in Cam-
eroun from two centres in 2010 to 9 centres in 2015, covering all but two provinces 
[26]. Twenty LFAC country programmes now claim near-universal national cover-
age of children with type 1 diabetes [27].
Globally, there are about 542,000 children under 15 years of age with type 1 dia-
betes and LFAC estimates that 112,000 of them are in need of support [15]. Our esti-
mated number of about 35,000 patients up to the age of 25 years who benefitted from 
donated insulin in 2015 therefore represents only a small part of the global need.
Donation programmes lead to better health outcomes
So far, only ten country programmes have reported data on the health impact of treat-
ment with donated insulin [14]. In Cameroon [28], Northern India [29], and Rwanda 
[30] the average body weight and/or body mass index increased from 4 to 23% over 
3 years. In Cameroun [28], mortality from diabetes-related causes decreased from 
an estimated 80% without insulin treatment to about 10% after 5 years of treatment. 
In Rwanda, mortality of registered patients was 6.2% after 5 years and 17.5% after 
10 years of treatment [21, 30]; Tanzania [22] and Guinea [25] had similar results.
The median value of the mean HbA1c (a measure of the average level of blood 
glucose over the last 2 to 3 months) of new patients entering the support programmes 
Fig. 1  Estimated number of patients with type 1 diabetes benefitting from donated insulin, in 43 low- and 
middle-income countries (2009–2015)
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was 11.5% (range 10.3–14%). The median reported value after 1–3 years of treatment 
was 8.4% (range 7.9–9.8%), and 9.5% (range 8.2–10.43%) after 6–8 years. The larg-
est reductions usually appeared in the first year of treatment. Overall, the proportion 
of patients with high HbA1c values (> 11%) decreased from 72 to 50% in Tanzania 
[23] and from 30.8 to 9% in Rwanda [21]. The frequency of serious complications also 
decreased: among 104 patients in Cameroon [26, 28] the annual frequency of serious 
hypoglycaemia reduced from 26 to 14.4%, and serious ketoacidosis from 29.8 to 6.7% 
over 5 years. In Tanzania [23], serious ketoacidosis decreased from 10 to 0.6%.
The Nepal programme reports that 90% of treated children attend school ‘normally’ 
(likely meaning regularly and with reasonable results) [31] and in Guinea delayed 
puberty and delayed growth decreased [25]. Yet in Ghana [32], Haiti [33], and Tanza-
nia [23] only half the children and youth attend school regularly, and in Haiti [33] 92% 
attend a grade level inappropriate for their age. In Tanzania, 32.6% missed school and 
three-quarters showed poor performance [23].
Thus, the health impact of donation programmes is positive when compared with 
the certain death the children would otherwise have faced. Yet treatment often remains 
partially insufficient and more needs to be done. For example, the first diagnosis can 
easily be missed due to inadequate health worker knowledge or absence of diagnos-
tic materials, and median HbA1c values of 9.5% after 6–8 years of treatment are well 
above target values in high-income countries. A large proportion of children and youth 
are not fully stabilized and continue to suffer from higher levels of acute and chronic 
complications than fully stabilized children in high-income countries, although these 
have become less frequent; their school attendance and performance are not optimal.
Insulin donation programmes can lead to changes in national health 
systems
In 2013, an independent evaluation of LFAC [15] concluded that the country pro-
grammes have led to better training, more free care, and health systems that are bet-
ter able to deal with diabetes. Experience in a small number of countries suggests 
that this is indeed the case. In 2017, the government of Tanzania took over the pro-
curement and supply of insulin and established a special unit for non-communicable 
diseases in the Ministry of Health, with six staff. Diabetes prevention and care in 
Tanzania is increasingly being integrated with clinics for HIV, tuberculosis, leprosy, 
dental care, and nutrition [22]. Such experiences can serve as an example for the 
many LMIC that still depend on insulin donations.
Public reporting is scattered, incomplete, and sometimes 
inconsistent
The level of reporting on the support programmes varies greatly between compa-
nies, programmes, countries, and years. When insulin donations are mentioned, 
the types and quantities are rarely specified. When the value of insulin donations 
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are disclosed, it is not clear whether the amounts are based on retail sale prices in 
OECD countries, or on international not-for-profit whole-sale prices as required 
by WHO [34]. Only in recent years have an increasing number of papers and con-
ference presentations described the magnitude and health benefits of support pro-
grammes. The scientific quality of these papers is not very high: none had a control 
group, many were simple ‘pre-post’ studies, and the rest were ‘post-only’. This lack 
of scientific rigour is consistent with a recent systematic review of company reports 
on the impact of ‘access’ programmes, which found that 62% of evaluations were of 
low and 32% were of very low quality [35].
Are insulin donation programmes sustainable?
The rising number of surviving young adults with type 1 diabetes in the countries 
with effective donation and support programmes now creates a sustainability chal-
lenge. There are two aspects to this: the sustainability of diabetes care and preven-
tion of complications for patients surviving and ‘aging out’ of the donation pro-
grammes (19/21 years of age for CDiC or 25 years for LFAC)—called ‘transition’; 
and the continuation of the financial support, including insulin donations, to the pro-
grammes in general.
In the LFAC evaluation, 31 (78%) of country programmes indicated that they 
cannot support individuals through the transition [15]. In response, several coun-
tries, such as Bangladesh, Tanzania, and Rwanda, have initiated specific activities 
to empower the surviving young adults to earn a living and look after themselves. 
These activities seem to be at least partly successful, but they are not yet part of all 
country programmes. With regard to programme sustainability, there are no signals 
that the major donors are considering withdrawal of their support. Novo Nordisk 
recently extended the CDiC programme beyond its original target date and expanded 
into five new countries (Cambodia, Ivory Coast, Myanmar, Senegal, and Sudan). Eli 
Lilly committed itself to insulin donations to the LFAC programme till 2019. There 
are currently no indications of a change in donor attitude.
And yet donation programmes, essential as they can be in certain situations, 
can never offer a permanent solution. For the patients and their families, free 
insulin is probably the most visible aspect of the support programme; it may even 
be the main reason for them to visit the clinic at all. However, the cost of insulin 
represents only one quarter of total supply costs (including also syringes, the glu-
cose meter and strips, and HbA1c testing) [36]. Free insulin has been an essential 
condition for success; but it is not sufficient and must be placed alongside many 
other essential supplies. And supplies are only part of diabetes care and preven-
tion of complications; equally essential are health professional education, public 
awareness, and psychosocial support.
In our view, the only sustainable future towards universal access in LMIC is inclu-
sion of standard diabetes care and prevention in national health insurance or social 
security programmes. Life-long treatment of chronic life-threatening diseases, such as 
diabetes, should be the highest priority when countries are establishing such schemes, 
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because in these cases out-of-pocket payments for the treatment and the risk of seri-
ous complications have a great potential to cause catastrophic health expenditure for 
uninsured patients and their families. As long as such schemes do not exist or only 
offer coverage to part of the population, insulin donation programmes can serve a very 
important purpose, leading to great health benefits to individual patients and their fami-
lies, and contributing to population health as a whole.
To facilitate the change from donation programmes to national health systems, we 
present a first outline of a ten-step process towards a fully sustainable national pro-
gramme for diagnosis and treatment of diabetes type 1 and the prevention and treat-
ment of its complications (Box 1). This proposal is largely based on the experiences 
of some donation programmes described above, and especially on the progress being 
made in Tanzania. It builds on the increasing visibility, status, and reputation of these 
programmes with national health policy makers, and on the empowerment of health 
care workers and patients. We acknowledge that it can never cover all complexities of 
national programmes and the many differences between countries. Yet, in countries 
where the donor-supported programme has reached near-national coverage, the man-
agers and diabetes specialists of these programmes have often established good con-
tacts with the national government and are now in a position to propose a step-by-step 
transfer of responsibility. This is especially relevant at the time when a government is 
moving towards universal health coverage through national health insurance or social 
security schemes. In these countries, our ten-step process may serve as a basis for a 
plan of action for the government, and as a perspective for the national NGO and exter-
nal donors; it could also serve as a yardstick to measure progress.
A final word about the role of the pharmaceutical industry. The fact that only 
three companies produce 92–93% of all insulin consumed in the world [3] creates a 
virtual monopoly that allows them to maintain high prices in most countries (or even 
increasing them, as in the USA), with very little room for competition by generic 
or biosimilar products. In the 2018 Access to Medicine Index, Eli Lily is ranked in 
20th (lowest) position, with below-average scores on product donations and equi-
table pricing, reaching only one quarter of target countries. Novo Nordisk is in 6th 
place, with high scores on product donations and capacity building, but not doing 
very well on patents and pricing.
The positive impact of donation programmes to a relatively small number of poor 
and disadvantaged patients in LMIC, as described above, is in itself no reason for 
the global public health community not to expect, or demand, from the pharmaceuti-
cal industry a system of equitable pricing policies as well. For example, lower insu-
lin prices for national governments and social health insurance systems in LMIC, 
through intra-country differential pricing, would facilitate the inclusion of essential 
insulin products in the basic health care package for all citizens, probably removing 
the need for donations altogether.
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Box 1. Ten steps to phase out an insulin donation programme
 (1) In countries where the public sector is unable to provide insulin and where 
high prices in the private sector make insulin unaffordable, the pharmaceuti-
cal industry and other donors should support a national diabetes programme 
with a free basic package of patient education, diagnosis, and treatment 
for as many children and youth with type 1 diabetes as possible, thereby 
preventing the almost certain death they would otherwise face; and create 
a national patient register for follow-up and reporting.
 (2) The pharmaceutical industry and other donors should collaborate with the 
national diabetes programme to create a national continuum of care for type 
1 diabetes from childhood to early adulthood, e.g. by combining in every 
eligible country the CDiC donation programme (till age 18), the LFAC 
donation programme (till age 25), and the Base of the Pyramid and other 
insulin discount programmes (for adults).
 (3) The national diabetes programme should collaborate with the Ministry of 
Health to strengthen national health systems to prevent, diagnose, and treat 
acute and chronic complications of type 1 diabetes, e.g. by creating diabetes 
clinics in every district hospital.
 (4) Donors and the national diabetes programme should provide detailed infor-
mation on key aspects of the support programme, such as the number and 
basic characteristics of recipient patients; the number, type, and value of 
diagnostic tests and medicines donated; the nature and cost of other pro-
gramme activities supported; and basic health outcomes such as mortality, 
weight gain, mean HbA1c levels, and frequency of complications.
 (5) The national diabetes programme should deliver to the Ministry of Health, 
national health insurance systems, and donors the proof of concept that type 
1 diabetes can successfully and cost-effectively be diagnosed and treated in 
LMIC, with improved health outcomes for patients.
 (6) The national diabetes programme should support the Ministry of Health in 
developing and implementing a national diabetes policy and implementation 
plan, as a public commitment and guide for action towards achieving uni-
versal access to decentralized health services for the prevention, diagnosis, 
and treatment of diabetes, as part of the progressive realization of the right 
to health.
 (7) The national diabetes programme should encourage the government to 
include the diagnosis, care and treatment of diabetes in all social health 
insurance programmes.
 (8) The pharmaceutical industry should create or strengthen intra-country dif-
ferential pricing mechanisms to make essential insulin products affordable 
to national governments and social health insurance schemes.
 (9) The national diabetes programme should encourage the Ministry of Health 
to integrate the prevention, diagnosis, and treatment of diabetes and its 
complications with the delivery of nutritional advice and with services for 
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the prevention and treatment of other chronic conditions such as HIV, tuber-
culosis, leprosy, and hypertension.
 (10) The pharmaceutical industry and other donors should phase out their support 
to the national diabetes programme as soon as these objectives have been 
achieved.
Conclusion
Over the last decade, support programmes with a component of insulin dona-
tion have delivered the proof of concept that, contrary to common belief, diag-
nosis and treatment of type 1 diabetes and the prevention of debilitating and fatal 
complications in children are practically possible in low- and middle-income 
countries. Continued donor support is justified by the individual health ben-
efits achieved, by the contribution towards population health, by the valuable 
health system experience with early diagnosis and treatment of type 1 diabetes 
in LMICs, and by the learning opportunities offered by the future transition of 
donor-supported programmes into comprehensive NCD services.
Even so, donations can never offer a sustainable solution. Sufficient evidence 
has now been generated to start in earnest a discussion with national governments 
on the inclusion of standard diabetes care in social security or health insurance 
schemes. The pharmaceutical industry should support this development by using 
their monopoly position to make essential insulin products affordable to national 
governments and social health insurance schemes, through intra-country differ-
ential pricing. Preventing certain death and increasing the quality of life for the 
children of today by the regular supply of insulin is a real contribution towards 
population health of tomorrow. Social justice demands nothing less.
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